
Globus Medical GMED
$ 89.04
-1.57%
Annual report 2025
added 02-24-2026
Globus Medical Deferred Revenue 2011-2026 | GMED
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Globus Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.7 M | 22.1 M | 18.4 M | 14.1 M | 12 M | 8.12 M | 5.4 M | 2.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.7 M | 2.6 M | 13.8 M |
Quarterly Deferred Revenue Globus Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.3 M | 24 M | 17.2 M | 20.8 M | 19.8 M | 17.1 M | 18 M | 14.9 M | 13.5 M | - | 12.3 M | - | 11.8 M | 12 M | 9.67 M | 9 M | 8.65 M | 8.12 M | 8.12 M | 8.12 M | 8.12 M | 5.4 M | 5.4 M | 5.4 M | 2.79 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 755 K | 755 K | 755 K | 755 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24 M | 755 K | 9.42 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 12.42 | -4.46 % | $ 1.86 B | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 38.55 | 0.13 % | $ 5.74 K | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 8.31 | 1.4 % | $ 597 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
AdaptHealth Corp.
AHCO
|
59.8 M | $ 9.61 | -0.62 % | $ 1.3 B | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 4.19 | -1.41 % | $ 156 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
14 K | $ 29.15 | -0.24 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.27 | -0.82 % | $ 113 M | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.59 | 0.3 % | $ 122 M | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 0.5 | -4.78 % | $ 51.4 M | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Cytosorbents Corporation
CTSO
|
419 K | $ 0.81 | 1.91 % | $ 44.1 M | ||
|
Align Technology
ALGN
|
1.33 B | $ 175.78 | -3.51 % | $ 13.2 B | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 3.7 | -8.31 % | $ 783 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 13.49 | -0.55 % | $ 872 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
313 M | $ 72.61 | 0.55 % | $ 107 B | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 1.4 | -0.71 % | $ 22.6 M | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 100.27 | -4.6 % | $ 1.27 B | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 2.26 | -2.16 % | $ 1.37 M | ||
|
Pulmonx Corporation
LUNG
|
135 K | $ 1.61 | 12.07 % | $ 63 M | ||
|
Inogen
INGN
|
5.48 M | $ 6.53 | 3.41 % | $ 174 M | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 64.29 | -1.49 % | $ 3.51 B |